What our observations and the evidence base do strongly suggest, however, is that, it is logical to use proven, effective, and safe treatments for sJIA, i.e., IL-1 or IL-6 blockade, sooner rather than later, and particularly early in the disease course when systemic features dominate the clinical picture. This evidence concerns the gene IL6 and systemic-onset juvenile idiopathic arthritis.